PEspeaks

Feb 27, 2015
Thanks to Shire's star drug Vyvanse, if you don't know much about binge-eating disorder, you soon will, writes Marylyn Donahue.
Feb 26, 2015
FDA officials have been busy rolling out advisories for pharma marketers, and there’s no let-up in sight, writes Jill Wechsler.
Feb 25, 2015
Drug shortages are declining, but they’re still a serious concern for regulatory authorities, policy makers and biopharma manufacturers, writes Jill Wechsler.
Applied Clinical Trials: Feb 22, 2015
Moe Alsumidaie looks at data collection methods and concepts that can result in predicting patients at risk of dropping out from a clinical trial.
Feb 12, 2015
The European Commission’s (EC) decision to withdraw its investigation into the UK Government's Patent Box scheme is positive news for British innovators, writes Michael Jaeger.
Feb 12, 2015
The ongoing battle over drug reimbursement and pricing has raised questions about whether the pharmaceutical industry can continue to rely on high U.S. revenues to fund biopharmaceutical R&D, writes Jill Wechsler.
Applied Clinical Trials: Feb 09, 2015
A new analysis shows South Korea to be the most attractive early phase destination based on the availability of global and regional suppliers, patient pool and the current regulatory scenario of the country.
Feb 09, 2015
The heart failure health area is set to expand from $2.9 billion in 2013 to $8.9 billion in 2023, writes Josh Baxt.
Feb 03, 2015
President Obama has unveiled his $215m “Precision Medicine Initiative” to support the future biomedical research, while calling for a reduction in exclusivity on brand biologics from 12 to 7 years and a curb on "evergreen” patents on certain biologics. Jill Wechsler reports.
Feb 03, 2015
This year's J.P. Morgan Conference in San Francisco showed that smaller “stealth pharma” players are beginning to show solid organic growth. William Looney reports.